longevitywatch
← All podcasts

Ben Greenfield Life

hosted by Ben Greenfield

We tested 58 claims from Ben Greenfield Life against the research. 3 held up, 6 did not, and the rest are partly true or still too early to judge.

What a speaker claims elsewhere is on their own profile.

We only test the claims that can be checked, not everything that is said. This is not a ranking.

Ben Greenfield · hosts Ben Greenfield Life

American author, entrepreneur and former triathlete in fitness and health

Partly
“Plants burden the body with toxins and stressors that act as a form of hormetic stress.”
Ben Greenfield (American author, entrepreneur and former triathlete in fitness and health) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
Several studies confirm that plant compounds (phytochemicals) are naturally toxic substances that protect plants against insects and other threats, and that at low doses they activate the same stress-response pathways in humans and animals as fasting or exercise. This mechanism is called hormesis and is well described in the scientific literature. The claim is therefore essentially correct. However, it goes somewhat beyond what the evidence justifies: much of the research has been conducted on cultured cells in the laboratory and in animal studies, and in humans it currently rests mainly on population research and theory. Moreover, the claim refers to "toxins and stressors" as two separate things, whereas the research shows that they are one and the same: the plant compound is the mild stressor precisely because it naturally serves a toxic function.

David Perlmutter

Neurologist and author

✗ Does not hold up
“In a three-year study, patients who received medication to treat amyloid actually declined faster.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · repeated in November 2026 · stated with confidence
Several large review studies in humans show precisely the opposite: the latest anti-amyloid antibodies slow the decline in patients with early or mild Alzheimer's disease compared to a placebo. There is, however, one exception: BACE inhibitors, a different type of amyloid medication that works by blocking a specific enzyme, were indeed associated with cognitive decline in patients in human studies. The claim that amyloid medications cause people to decline faster is therefore not valid as a general statement about this drug class; for antibody therapies, the evidence points in the other direction, while for these enzyme inhibitors the picture is more nuanced.
Partly
“Parkinson's disease is an inflammatory disease of the nervous system caused by malfunctioning mitochondria.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
Research confirms that both inflammation in the nervous system and problems with mitochondria (the energy centres of cells) play a role in Parkinson's disease, and several review studies show that these two processes reinforce each other. The claim is therefore correct in its direction, but overly simplistic. Studies describe Parkinson's as a complex disease in which protein accumulation, damage from free radicals and disrupted waste disposal within cells also play a part. Moreover, mitochondrial dysfunction is not the sole or established cause, but one of several factors contributing to the disease process, and research makes clear that the original cause of the neuroinflammation is still a matter of debate. → Does exercise help with Parkinson's disease?
Partly
“According to a Cochrane analysis of seventeen studies, drugs that remove beta-amyloid are ineffective.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
The Cochrane analysis (a systematic review registered under number 41985900) does indeed cover seventeen studies and concludes that the effect on cognitive ability and dementia severity after eighteen months is negligibly small, and that successfully removing beta-amyloid does not lead to any noticeable improvement in practice. The claim that the drugs are "ineffective" is therefore largely accurate for the group studied. That said, this wording goes slightly further than the review itself: a small positive effect is found for daily functioning, and the review rates the quality of the evidence for effectiveness as moderate to low. Furthermore, other studies (registered under numbers 38017568 and 39865265) show that newer drugs such as lecanemab and donanemab do have measurable effects on certain outcomes, although these remain too small to make a difference in everyday practice. The claim is therefore a defensible summary of the Cochrane review, but lacks the nuance that "ineffective" here means that the effects are negligible in practice and that for some outcomes the evidence is of limited quality.
✓ Holds up
“The blood-brain barrier becomes more permeable as people age.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
Several studies in humans support this claim. An MRI study of healthy middle-aged to older adults found that greater age was associated with increased permeability of the blood-brain barrier, in both white and grey matter. Another study in living humans demonstrated age-related breakdown of the blood-brain barrier in the hippocampus. Several reviews confirm that structural and functional deterioration of the blood-brain barrier is a normal part of the ageing process, and animal research points in the same direction. The claim therefore accurately reflects the state of the research.
Partly
“As people age, microglial cells become increasingly polarised towards the pro-inflammatory M1 phenotype.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
Research shows that microglial cells, the brain's immune cells, change with age and become increasingly pro-inflammatory. However, an authoritative publication co-authored by dozens of experts argues that the strictly binary classification of microglial cells into a 'pro-inflammatory' group and an 'anti-inflammatory' group is outdated and overly simplistic. Microglial cells exist across a broad spectrum of intermediate states that do not fit neatly into two separate categories. The claim that cells shift ever further towards the 'pro-inflammatory' side therefore relies on a classification that the field has since abandoned. Moreover, most of the studies cited are largely based on animal models or on people with brain diseases, rather than exclusively on healthy people who are simply growing older. As a result, the claim goes beyond what the available evidence in healthy people directly supports.
Partly
“Beta-amyloid in the brain is neither necessary nor sufficient to cause Alzheimer's disease.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · repeated in November 2026 · stated with confidence
Research in humans and in mice bred specifically for this type of study does indeed show that removing beta-amyloid from the brain does not lead to a measurable improvement in memory or halt other forms of damage, suggesting that amyloid alone is not sufficient to cause or sustain Alzheimer's disease. The claim that amyloid is also not necessary goes a step further: studies actually emphasise that amyloid plays a central role as the starting point of a cascade of damaging processes in the brain, and that hereditary forms of Alzheimer's disease and Down syndrome support this. The claim is therefore correct in stating that amyloid is not sufficient, but the research does not show that amyloid is also dispensable for the onset of the disease.
Partly
“Fine particulate matter of the PM2.5 type can enter the brain directly through inhalation via the cribriform plate in the nose.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
That fine particulate matter reaches the brain and causes damage there is well established: several large review studies link exposure to PM2.5 to a higher risk of dementia and cognitive decline. However, the specific route via the cribriform plate in the nose is one of the mechanisms discussed in the scientific literature, but that precise pathway has not yet been proven conclusively. It is more plausible that fine particulate matter reaches the brain via multiple routes, including through inflammatory responses and oxidative stress in the blood.
✗ Does not hold up
“Oral semaglutide reduced C-reactive protein levels by 30% in Alzheimer's patients.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
The studies that investigated precisely this were two studies on semaglutide in tablet form in people with early-stage Alzheimer's disease. These studies do show a measurable, significant decrease in an inflammatory marker in the blood (C-reactive protein), but do not mention a percentage of 30%. The decrease in patients with diabetes and a high risk of cardiovascular disease, examined in a separate study, was approximately 23% after three years compared to a placebo. The claim mentions Alzheimer's patients and the figure of 30%, but neither is correct based on the available research results.
Partly
“Administering RNS60 intravenously reduces the size of the cerebral infarct in patients undergoing thrombectomy.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
A phase 2 study involving 82 patients who underwent thrombectomy (a procedure in which a blood clot is removed from a blood vessel) shows that the higher dose of intravenous RNS60 significantly reduced the growth of the cerebral infarct compared to a placebo. The claim is therefore correct in its direction and concerns humans. However, this was a small-scale study designed primarily to assess the safety of the drug, and the researchers themselves conclude that a larger, better-designed study is needed to confirm the effect. Moreover, the result applied only to the higher dose, not the lower one, and other measurable outcomes showed no clear difference.
Partly
“The GLP-1 agonist lixisenatide led to stabilisation or slight improvement of symptoms on a standardised disease scale in Parkinson's patients over the course of a year.”
David Perlmutter (Neurologist and author) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
A small trial with lixisenatide in Parkinson's patients has indeed been conducted, and the direction of the claim is consistent with the positive signals that are sometimes found in smaller studies. However, research into GLP-1 agonists in Parkinson's disease as a whole shows mixed results: the largest randomised trial, using the related drug exenatide, found no slowing of the disease. The claim that the lixisenatide trial would show results of stabilisation or improvement cannot be substantiated on the basis of the available evidence, while the published results of that trial are not yet listed in the registry either. It is therefore too early to present the claim as stated as an established fact.

Dr. Tyna Moore

Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine

Partly
“GLP-1 agonists stimulate remyelination of nerve cells and have a neuroregenerative effect.”
Dr. Tyna Moore (Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Animal studies do show indications that GLP-1 agonists have protective and restorative effects on nerve cells, but the claim goes further than the evidence justifies. Remyelination specifically has not yet been demonstrated in humans, and for neuroregeneration in a broader sense the clinical results to date are mixed: the largest randomised trial in Parkinson's disease was negative. Whether these drugs also have a meaningful neuroregenerative effect in humans remains to be shown by larger and better-designed research.
Partly
“GLP-1 agonists influence reward pathways in the brain and can reduce cravings for addictive substances such as alcohol and nicotine.”
Dr. Tyna Moore (Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · repeated in November 2026 · stated with confidence
The claim has a solid core: animal studies consistently point to reduced alcohol and nicotine use, and large analyses of patient data show an association in humans with fewer care contacts for addiction. The idea that GLP-1 agonists influence reward pathways in the brain is a plausible mechanism that supports these signals. Nevertheless, the claim goes further than the evidence justifies: clinical trials in humans are scarce and yield mixed results, and several early trials are currently underway with no published results yet. The effect on cravings has therefore not yet been established as a confirmed clinical fact.
Too early
“GLP-1 agonists improve the elasticity and mitochondrial function of cardiomyocytes in heart tissue.”
Dr. Tyna Moore (Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Several laboratory and animal studies show that GLP-1 agents such as liraglutide, semaglutide and exendin-4 improve mitochondrial function in heart cells: they restore energy production, reduce mitochondrial damage and protect cardiomyocytes in cell cultures and in mice and rats. However, these studies say nothing about the flexibility of cardiomyocytes. Furthermore, this effect has not yet been tested in humans in large-scale clinical research specifically focused on mitochondrial function or cellular flexibility in heart tissue, whereas the claim suggests this is already an established effect in humans. → Can GLP-1 agonists improve heart function?
Partly
“Large-scale data show no causal link between the use of GLP-1 agonists and suicidal thoughts.”
Dr. Tyna Moore (Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Large studies indeed show no increased risk of suicidal thoughts with GLP-1 agonists, and several of them actually find a lower risk. The absence of this association is broadly supported by the available research. However, "no causal link has been demonstrated" is phrased somewhat more strongly than what the studies actually offer: observational and large-scale evidence can map associations, but such studies do not prove causality in the strict sense. One exception has moreover been noted in the research, although that finding is likely explained by the patients' own psychiatric history.
Partly
“Drastic caloric restriction and rapid slowing of gastric emptying caused by high doses of GLP-1 agonists increase the risk of gallbladder sludge, gallstones and secondary pancreatitis.”
Dr. Tyna Moore (Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
The increased risk of gallstones with GLP-1 agonists is well supported: prolonged use of drugs such as semaglutide or dulaglutide is associated with a moderately increased risk. The link to caloric restriction and delayed gastric emptying as a combined cause is a mechanistic explanation added by the claim, but that line of reasoning has not been tested as such in the available research. That gallstones can subsequently lead to pancreatitis is well known, but the larger and better-designed studies show no increased risk of pancreatitis with GLP-1 agonist use. The claim presents the pathway to secondary pancreatitis as a demonstrable risk, whereas the evidence for this is not solid.
Partly
“GLP-1 agonists can promote the regeneration of cells in the pancreas.”
Dr. Tyna Moore (Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with caution
In animal studies, the restorative effect of GLP-1 agonists on beta cells in the pancreas has been convincingly demonstrated. In humans, that effect has not yet been confirmed: used alone, they do not measurably increase beta cell production. The claim that GLP-1 agonists 'can promote' regeneration therefore holds for rodents, but anyone who reads this as a proven effect in humans is going further than the research has shown so far.
Partly
“GLP-1 agonists cause upregulation and translocation of GLUT4 glucose transporters to the cell membrane.”
Dr. Tyna Moore (Naturopathic doctor and specialist in GLP-1 agonists and regenerative medicine) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Several laboratory and animal studies show that GLP-1 and drugs resembling GLP-1, such as exenatide and liraglutide, do indeed cause more GLUT4 to reach the outer surface of cells and that muscle and fat cells produce more GLUT4. This applies both to cells cultured in the lab, including human muscle cells, and to rats and diabetic mice. Even so, the claim goes slightly beyond the evidence: the studies also show that the effect depends on the circumstances, such as whether insulin resistance is present, and that the precise mechanism differs from study to study. Whether both effects occur equally strongly in humans in everyday life has not yet been tested in large studies with real patients.

Gary Brecka

Human biologist and longevity expert, former mortality predictor in the life insurance industry · Who he is, what he sells, where he stands →

Partly
“Brief exposure to hypoxic conditions or altitude improves oxygen transport by stimulating erythropoiesis.”
Gary Brecka (Human biologist and longevity expert, former mortality predictor in the life insurance industry) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Research in humans shows that repeated brief exposure to low-oxygen air (for example three sessions of 90 minutes per week over three weeks) can increase the production of the hormone that stimulates red blood cells and yields measurable improvements in red blood cell mass. Several studies do qualify this, however: results are inconsistent and depend strongly on the altitude, the duration and the frequency of exposure. For a clear effect on red blood cell production, it appears that at least more than 12 hours per day at a sufficient altitude for at least three weeks is necessary, and with shorter or less intense exposure blood values sometimes remain unchanged. The claim that brief exposure improves oxygen transport is therefore broadly correct, but it misses the important caveat that the outcome depends strongly on the precise dosage.
Partly
“Type 2 diabetes develops in a hypoxic (oxygen-deprived) environment.”
Gary Brecka (Human biologist and longevity expert, former mortality predictor in the life insurance industry) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Research shows that oxygen deficiency plays a role in type 2 diabetes, but the relationship is more complex than the claim suggests. For instance, one review study (38673770) describes that oxygen deficiency occurs in the insulin-producing cells of people with type 2 diabetes and contributes to the loss of those cells, while another review (27419143) discusses the role of oxygen deficiency in tissue and throughout the body in obesity and type 2 diabetes. A third review (42553224) argues that oxygen deficiency caused by high blood sugar is in fact a consequence of diabetes and subsequently drives kidney damage. The claim reverses the order: oxygen deficiency appears to be part of a vicious cycle rather than the sole or primary cause of type 2 diabetes.
✗ Does not hold up
“All forms of cancer begin and develop in a hypoxic (oxygen-deprived) environment.”
Gary Brecka (Human biologist and longevity expert, former mortality predictor in the life insurance industry) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Research shows that hypoxia is a common feature of solid tumours and plays an important role in cancer progression and spread, but the claim that all forms of cancer begin and develop in an oxygen-deprived environment is incorrect. Hypoxia is described as a feature of tumour growth and the tumour microenvironment that arises after a tumour is already developing, not as the necessary starting environment for every type of cancer. One review explicitly states that the hypoxic environment forms early in tumour growth, but not that this environment triggers the onset of cancer. Moreover, several studies describe the so-called pseudo-hypoxia phenomenon, in which cancer cells activate hypoxia signals themselves without there actually being an oxygen-deprived environment, demonstrating that cancer can also occur without true hypoxia.
Partly
“A urolithin A supplement reduces systemic inflammation and recharges mitochondria in immune cells.”
Gary Brecka (Human biologist and longevity expert, former mortality predictor in the life insurance industry) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Urolithin A has a biologically plausible mechanism through the clearance of damaged mitochondria, and small human studies show cautiously positive signals for mitochondrial health and muscular endurance. However, the claim goes beyond the available evidence: effects on systemic inflammation in humans have not been demonstrated in the studies, and the research comes largely from the manufacturer itself, without independent confirmation. The specific idea of 'recharging mitochondria in immune cells' has not yet been tested in humans.
Partly
“Urolithin A stimulates mitophagy, the process by which damaged mitochondria are cleared and recycled.”
Gary Brecka (Human biologist and longevity expert, former mortality predictor in the life insurance industry) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Urolithin A does indeed have a plausible mechanism of action through the clearance of damaged mitochondria, which is what mitophagy is. That mechanism is also the starting point in research into this supplement. However, 'stimulates mitophagy' presents this as an established fact, whereas the evidence in humans is still limited and the studies have largely been funded by the manufacturer without independent confirmation. The claim points in the right direction, but goes beyond what the current evidence firmly supports.
Partly
“Around the age of twenty, the thymus begins to shrink (involution), leading to reduced T-cell production and immune ageing.”
Gary Brecka (Human biologist and longevity expert, former mortality predictor in the life insurance industry) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
The fact that the thymus shrinks and consequently produces fewer new T-cells, causing the immune system to decline with age, is well documented and broadly confirmed by human studies. However, 'around the age of twenty' as a starting point is stated more precisely than the research supports: the findings describe a gradual process without specifying an exact age of onset. The direction of the claim is correct, but that precise threshold of twenty years cannot be substantiated.

Dr. Amy Hornaman

Doctor in clinical nutrition and specialist in functional medicine and thyroid disease

Partly
“Sufficient testosterone protects against autoimmune reactions and helps lower Hashimoto antibodies.”
Dr. Amy Hornaman (Doctor in clinical nutrition and specialist in functional medicine and thyroid disease) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
There is one small medical study in men with Hashimoto's disease and low testosterone showing that testosterone treatment lowered thyroid antibodies. Several review articles confirm that androgens suppress the immune response and that autoimmune diseases are more common in women, which is consistent with a protective role of testosterone. However, the claim goes beyond what the evidence supports: the protective effect has so far only been demonstrated in men with testosterone deficiency, not in people with normal testosterone levels, and the studies say nothing about whether this also applies to women or other groups. Moreover, the evidence is largely based on small studies and review articles, which means the conclusion is not sufficiently substantiated to stand as a general statement.
Partly
“Prolonged carbohydrate restriction to below 20 to 30 grams per day leads to a reduction in free T3 production.”
Dr. Amy Hornaman (Doctor in clinical nutrition and specialist in functional medicine and thyroid disease) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Several studies in humans show that carbohydrate restriction or a ketogenic diet lowers T3 levels. T3 is a thyroid hormone. For example, T3 dropped by an average of around 35% in obese women on a low-carbohydrate diet, and a marked decrease in T3 was also found in healthy subjects on a ketogenic diet. The claim is therefore correct in its direction. However, it goes beyond the evidence on two points: not all studies use the threshold of 20 to 30 grams of carbohydrates per day, and in most studies the focus is on total T3 or free T3 in the context of reduced conversion of another thyroid hormone to T3, not exclusively on the "production" of free T3. Caloric restriction also plays a role alongside carbohydrate restriction in many studies, which means the effect cannot be attributed entirely to carbohydrate restriction alone.
Too early
“The thyroid hormone T2 stimulates brown adipose tissue and burns fat while preserving muscle mass, without suppressing the body's own thyroid production.”
Dr. Amy Hornaman (Doctor in clinical nutrition and specialist in functional medicine and thyroid disease) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Research into T2 and fat burning, brown adipose tissue and muscle preservation has so far been conducted exclusively in rats. Those studies do show that T2 activates brown adipose tissue in rats, converts white fat cells into cells more closely resembling brown adipose tissue, and at the same time spares muscle mass. The fact that T2 does not suppress the body's own thyroid production, the so-called non-thyrotoxic effect, has also been studied in rat studies and is described as an advantage. Whether these effects also occur in humans has not yet been tested in research with human subjects.
Partly
“Reverse T3 blocks the action of the active thyroid hormone T3 at the cellular level.”
Dr. Amy Hornaman (Doctor in clinical nutrition and specialist in functional medicine and thyroid disease) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Research shows that rT3 binds weakly to thyroid hormone receptors in cells and, in laboratory studies using rat cells, can block the action of T3, which supports the direction of the claim. However, review studies and research in humans describe rT3 primarily as a biologically inactive waste product that indirectly reduces the action of T3, partly by keeping the thyroid hormone T4 away from conversion to active T3. Whether rT3 blocks T3 directly in human cells on a large scale has not yet been established: one review study mentions this as a possibility, but emphasises that the evidence for it remains limited. The claim presents this as an established fact, whereas research in humans has not yet demonstrated this mechanism conclusively.

Dr. Sandra Kaufmann

Anesthesiologist and specialist in cellular aging and longevity

Partly
“Hydralazine scavenges free glucose molecules and thereby inhibits the formation of Advanced Glycation End-products (AGEs).”
Dr. Sandra Kaufmann (Anesthesiologist and specialist in cellular aging and longevity) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Research shows that hydralazine inhibits AGE formation, but the mechanism is more complex than simply scavenging free glucose molecules. Studies in diabetic rats and mice show that hydralazine lowers AGEs through 'transglycation' (detaching glucose from proteins) and by scavenging reactive carbonyl compounds such as glyoxal and methylglyoxal, not primarily free glucose. Cell studies even show that hydralazine does not effectively scavenge glyoxal itself, but instead acts as an antioxidant. The claim that hydralazine specifically scavenges free glucose molecules is therefore not fully correct: the active mechanisms are different and have moreover been demonstrated mainly in animal and cell studies, not in humans.
Partly
“Pioglitazone mobilizes visceral fat and moves it to subcutaneous fat compartments.”
Dr. Sandra Kaufmann (Anesthesiologist and specialist in cellular aging and longevity) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Several human studies show that pioglitazone favourably alters the ratio of visceral to subcutaneous fat: visceral fat decreases or increases relatively less, while subcutaneous fat increases. One study in people with diabetes shows that visceral fat decreased and subcutaneous fat increased after treatment. However, another study in non-diabetic people with overweight shows that the improvement in fat distribution is driven mainly by an increase in fat in the lower body regions, not by genuine mobilization of visceral fat. The claim that pioglitazone actively 'mobilizes' visceral fat and moves it to another compartment goes beyond what the studies demonstrate: it is more a matter of redistribution in which newly stored fat is preferentially deposited subcutaneously, rather than a direct transfer of existing visceral fat.
Partly
“Magnesium L-threonate crosses the blood-brain barrier and increases synaptic plasticity in the hippocampus.”
Dr. Sandra Kaufmann (Anesthesiologist and specialist in cellular aging and longevity) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Research shows that magnesium L-threonate (MgT) reaches the brain more effectively than common forms of magnesium, and that small human studies show cautiously positive effects on memory and cognition. The claim regarding crossing the blood-brain barrier is therefore supported. However, the specific mechanism mentioned in the claim, namely increasing synaptic plasticity in the hippocampus, comes from animal research and has not yet been convincingly demonstrated in humans. The evidence for such a categorical claim remains too limited.
Partly
“Higher lithium levels in drinking water and food are linked to a lower risk of dying.”
Dr. Sandra Kaufmann (Anesthesiologist and specialist in cellular aging and longevity) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Population research offers tentative indications that low doses of lithium, such as those found in drinking water, are associated with less cognitive decline and possibly beneficial health effects. However, the claim that higher lithium levels correlate with lower all-cause mortality goes beyond what the available research can confirm with certainty: the results are mixed and the studies are preliminary in nature. There is no strong evidence that this association holds for the broad category of all causes of death.

Chad Robichaux

Founder of the Mighty Oaks Foundation and former Force Recon Marine

Partly
“A medically supervised intravenous ketamine infusion can help retrieve memories from the past and reprocess them.”
Chad Robichaux (Founder of the Mighty Oaks Foundation and former Force Recon Marine) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with caution
Research shows that ketamine, including when administered intravenously, influences the way traumatic memories are stored and updated, and that this may be useful in treating post-traumatic stress disorder. A review study describes how ketamine can facilitate the reprocessing of distressing memories, and a small study in humans (eight participants) shows that ketamine combined with trauma therapy reduces post-traumatic stress disorder symptoms. However, the claim made in the podcast states specifically that a ketamine infusion helps to "retrieve and reprocess" memories: in this research, retrieving memories is not a separate goal in itself, but part of a combined approach with psychotherapy. Moreover, the only study in humans used ketamine dissolved under the tongue rather than administered intravenously, and the researchers themselves indicate that larger studies with randomised group allocation are needed before further conclusions can be drawn.
Partly
“Therapy with psilocybin or ibogaine under medical supervision can be used to treat addiction.”
Chad Robichaux (Founder of the Mighty Oaks Foundation and former Force Recon Marine) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with caution
For psilocybin there are promising signals in alcohol and tobacco addiction, but the evidence comes primarily from small studies without adequate control groups, and long-term safety has not been properly mapped. For ibogaine in opioid addiction, evidence from controlled research in humans is entirely lacking, and the cardiac risks are serious and well documented, including fatalities. Medical supervision is indeed an absolute requirement, not a minor consideration, but even then the evidence for both substances as a treatment for addiction is still too limited to speak of an established treatment option.
Partly
“Ibogaine acts strongly on serotonin receptors and other neurotransmitters, which may help reduce addictive tendencies.”
Chad Robichaux (Founder of the Mighty Oaks Foundation and former Force Recon Marine) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with caution
Ibogaine does indeed act through multiple pathways in the brain, and there are indications that it can reduce drug craving and withdrawal symptoms. The claim places the emphasis on serotonin receptors, but research shows that ibogaine's mechanisms of action are in fact highly diverse and not yet well understood. The claim that its effects on addictive tendencies have been clinically proven goes beyond the available evidence: controlled studies in humans are largely lacking, and only a handful of early trials are currently underway. Furthermore, the claim omits the most important caveat: ibogaine carries a serious risk of fatal cardiac arrhythmias.

Chad Robichaux, Alan John Buckley & Jimmy St. Louis

Former Force Recon Marine, actor and entrepreneur in health and longevity

Partly
“Training in the afternoon increases insulin sensitivity, which carries over into dinner.”
Chad Robichaux, Alan John Buckley & Jimmy St. Louis (Former Force Recon Marine, actor and entrepreneur in health and longevity) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
Evening exercise does indeed have the best-documented benefits for blood sugar, but the available research looks at the effect of weeks of regular training, not at the direct carry-over effect on blood sugar processing during the meal that follows a single specific workout. The claim suggests a concrete mechanism: afternoon training increases insulin sensitivity, which directly carries over to dinner. However, that time-bound link cannot be firmly established on the basis of the research. The direction is right, but the precision about the timing and the direct carry-over to the evening meal goes beyond what the evidence supports.
Partly
“Reaction speed, testosterone levels and body temperature peak between 4 p.m. and 6 p.m.”
Chad Robichaux, Alan John Buckley & Jimmy St. Louis (Former Force Recon Marine, actor and entrepreneur in health and longevity) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
Several review studies in humans show that body temperature and physical performance peak in the late afternoon or early evening, and research also points to the evening as the optimal time for reaction speed. For testosterone, the picture is different: its peak occurs early in the morning, not between 4 p.m. and 6 p.m., and sleep disruption shifts that peak to the moment of waking, not to the afternoon. The claim that all three factors peak between 4 p.m. and 6 p.m. is therefore too broad: for testosterone this is not supported by available research, and for reaction speed the evening rather than a specific two-hour window is cited.
Partly
“Tattoo ink can introduce microplastics and dyes into the bloodstream.”
Chad Robichaux, Alan John Buckley & Jimmy St. Louis (Former Force Recon Marine, actor and entrepreneur in health and longevity) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with caution
Microplastics demonstrably end up in human blood and tissues, and this is also biologically plausible for tattoo ink. As for the exact route via tattoos and which substances precisely enter the bloodstream in the process, this goes beyond what current research can establish with certainty. There are signals regarding health effects, but cause and effect have not yet been proven in humans, and this is all the more true for tattoo ink as a specific source.

Dr. Eric Westman & Jay Feldman

Dr. Eric Westman is associate professor of medicine at Duke University; Jay Feldman is health coach and independent health researcher

Partly
“The heart muscle naturally uses little glucose and prefers ketones and fatty acids as fuel.”
Dr. Eric Westman & Jay Feldman (Dr. Eric Westman is associate professor of medicine at Duke University; Jay Feldman is health coach and independent health researcher) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Several review studies confirm that the heart muscle under normal conditions indeed runs primarily on fatty acids: this is the dominant fuel source. Glucose also plays a meaningful role as a co-fuel, however, and is certainly not a negligible energy source for the heart. Ketones are described in the studies discussed as an alternative or supplementary fuel rather than a primary preferred fuel alongside fatty acids. The claim that the heart "naturally uses little glucose" is therefore only partially correct: glucose is a regular and relevant energy source, albeit a smaller one than fatty acids. Moreover, the preference for ketones over glucose is more strongly documented in situations of heart failure than in the healthy heart.
✗ Does not hold up
“When people in ketosis consume carbohydrates, their T3 thyroid hormone levels drop.”
Dr. Eric Westman & Jay Feldman (Dr. Eric Westman is associate professor of medicine at Duke University; Jay Feldman is health coach and independent health researcher) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
The claim reverses the order of events: it states that T3 drops when people in ketosis consume carbohydrates. What research in humans actually shows is the opposite: T3 drops when following a low-carbohydrate ketogenic diet, that is, when carbohydrates are omitted and the body enters ketosis. A randomised study in healthy adults and several studies in patients with epilepsy confirm that reduced T3 levels occur during ketosis, not as a result of eating carbohydrates while in ketosis. The claim therefore describes precisely the wrong direction of the effect.
Partly
“A higher content of unsaturated fatty acids in the mitochondrial membrane causes inefficient cellular respiration and increased oxidative damage.”
Dr. Eric Westman & Jay Feldman (Dr. Eric Westman is associate professor of medicine at Duke University; Jay Feldman is health coach and independent health researcher) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Research in rats and yeast cells shows that the amount of unsaturated fatty acids in the membranes of the cell's energy centres affects the efficiency of cellular respiration: both a deficiency and an excess can disrupt energy conversion. Comparative animal research also shows that animals with cell membranes containing fewer unsaturated fatty acids accumulate less oxidative damage and live longer, which supports the direction of the claim. However, the claim is too categorical: the studies show that the relationship is more complex and depends on the type of fatty acid, the quantity and the context, and this relationship has not yet been tested in humans.

Reza Jazayeri

orthopedic surgeon

✗ Does not hold up
“Supplementation with essential amino acids rich in leucine slows the loss of muscle mass and muscle strength during bed rest”
Reza Jazayeri (orthopedic surgeon) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Multiple randomised studies show that taking extra leucine does not counteract the loss of muscle mass and muscle strength during immobilisation or bed rest. Three controlled trials in young and older adults found no difference between leucine and a placebo in muscle mass or strength after limb immobilisation. One study in middle-aged adults did find a partial protective effect of leucine on muscle strength and muscle quality during 14 days of bed rest, but this effect was limited and partly disappeared after 14 days. A review study on essential amino acids combined with glutamine does see potential in taking those amino acids in patients in a clinical setting, but this concerns a different composition than leucine alone, and different groups of people. On balance, most direct research in humans indicates that taking extra leucine alone does not prevent muscle and strength loss during bed rest or immobilisation.
✓ Holds up
“Taking too much zinc for too long inhibits copper absorption in the intestines and can cause a copper deficiency”
Reza Jazayeri (orthopedic surgeon) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · repeated in September 2026 · stated with confidence
High zinc doses demonstrably block copper absorption in the intestines, with clinically proven consequences such as anaemia and, in severe cases, spinal cord damage. The evidence is solid for very high doses and plausible for prolonged use above the safe upper limit. The claim describes this mechanism correctly: the combination of prolonged use and excessive amounts is precisely where the risk lies.
Partly
“Healthy adults who are on strict bed rest for 28 days lose about half a percent of muscle mass per day, while older adults lose about one percent per day.”
Reza Jazayeri (orthopedic surgeon) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
A large study combining and comparing the results of many earlier studies shows that older adults lose more muscle mass during bed rest than younger adults, and that they do so more quickly. The direction of the claim is therefore correct. However, the stated percentages of half a percent and one percent per day are not confirmed by the summaries of those studies: the research reports absolute weight figures and measures of effect size, not daily percentages. Moreover, most studies looked at periods of 5 to 14 days, not 28 days. These studies therefore provide insufficient grounds for a claim about exact daily loss percentages after 28 days of bed rest. → How quickly do you lose muscle mass when you spend a long time in bed?

Dr. Ben Goertzel

Scientist and founder/CEO of SingularityNET, specializing in artificial general intelligence (AGI)

Partly
“A combination of Chinese herbs significantly lowers C-reactive protein (CRP) levels in human blood.”
Dr. Ben Goertzel (Scientist and founder/CEO of SingularityNET, specializing in artificial general intelligence (AGI)) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Several large summaries of carefully designed human studies show that Chinese herbal mixtures can lower the inflammatory marker CRP, but important caveats apply. For instance, one such summary in cardiovascular disease found a clearly measurable effect of herbal medicines on top of standard treatment, but no clear difference compared to a placebo when both groups were also taking Western medicines. Studies into specific herbal formulas, such as those for rheumatism or atherosclerosis, also show reductions in CRP levels, but always in combination with other treatments and in specific patient groups. The claim suggests a broad and unambiguous effect, whereas the evidence shows that the effect depends strongly on the composition of the herbal mixture, the condition being treated, and whether other medicines are also being used.
✗ Does not hold up
“A mixture of Chinese herbs can reverse moderate Alzheimer's disease to mild Alzheimer's disease in people.”
Dr. Ben Goertzel (Scientist and founder/CEO of SingularityNET, specializing in artificial general intelligence (AGI)) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with caution
Research into Chinese herbal medicines for Alzheimer's disease shows that they can improve memory and cognitive scores compared to a placebo or standard treatment, but no study demonstrates that the disease actually reverts from a moderate to a mild stage. Review studies that pool and compare large numbers of trials describe modest improvements on memory and cognitive rating scales, not a genuine reversal of disease stage. Furthermore, these review studies conclude that the quality of the evidence remains limited due to small study designs and methodological shortcomings, and that Chinese herbal medicines are best used as a complementary therapy rather than as a standalone treatment that reverses the disease.
Partly
“Gene therapy aimed at telomere lengthening can actually lengthen telomeres in the human body.”
Dr. Ben Goertzel (Scientist and founder/CEO of SingularityNET, specializing in artificial general intelligence (AGI)) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · shared as personal experience
That gene therapy aimed at telomere lengthening works in principle has been demonstrated in cell and animal studies: telomerase can compensate for telomere shortening and thus keep telomeres longer. In humans, however, clinical evidence is largely lacking, and there is a serious safety risk: the same mechanism that allows cells to survive longer can also fuel cancer cells. The claim is therefore correct in terms of what is biologically possible, but it overlooks the fact that 'actually lengthening telomeres in the human body' has not yet been properly proven outside the laboratory.

Dr. Abud Bakri

Internist and physician specialized in peptides and metabolism

Partly
“Long-term combination treatment with the peptides thymalin and epithalamin halved the mortality risk in elderly nursing home patients.”
Dr. Abud Bakri (Internist and physician specialized in peptides and metabolism) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Two studies from the same research group report a 2.5-fold reduction in mortality among 266 older adults who received both thymalin and epithalamin, which goes beyond halving. With annual combination treatment over six years, the reduction was even 4.1-fold. The claim that the risk "halved" therefore underestimates the reported effect rather than exaggerating it. Nevertheless, there are important caveats: all studies come from the same Russian research group, participants were not randomly assigned to groups and were aware of which group they were in, as is standard in well-designed research by current criteria. Furthermore, no other independent research group has replicated and confirmed the results. The claim is correct in terms of direction and order of magnitude, but presents the findings as established fact while the evidence has not yet been independently confirmed.
Partly
“A CD4 count above 800 combined with a CD4/CD8 ratio above 1 is associated with lower mortality and morbidity in ageing.”
Dr. Abud Bakri (Internist and physician specialized in peptides and metabolism) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Research in humans does indeed show that a low CD4/CD8 ratio is associated with higher mortality and more disease. Studies in people with HIV find that a ratio below 0.7 or 1.0 is associated with higher mortality and additional illnesses, and a study of 360 healthy older adults shows that an inverted ratio (below 1) is linked to poorer cognition and greater functional limitations. However, the evidence is not clear-cut: one prospective study in 85-year-olds found no association between an inverted ratio and three-year mortality, and a large study in older Americans shows that the association with mortality varies considerably by sex and ethnic background. The specific combination of a CD4 count above 800 and a ratio above 1 as a joint threshold has been examined in one HIV study but has not yet been broadly confirmed in the general older population, which means the claim goes beyond what the evidence currently demonstrates conclusively.
Partly
“A low lymphocyte-to-monocyte ratio (LMR) is correlated with an increased risk of morbidity and mortality in conditions such as diabetes and cancer.”
Dr. Abud Bakri (Internist and physician specialized in peptides and metabolism) · Ben Greenfield Life, October 2026 · watch the episode ↗︎ · stated with confidence
Several large studies, including review studies that pool the results of many individual studies, show that a low LMR is indeed associated with poorer survival in various forms of cancer, such as lung cancer, colorectal cancer and liver cancer, and also in liver cirrhosis with septic shock. Research also links LMR to the recurrence of colorectal cancer in people with diabetes. The claim therefore holds for cancer and partly for serious complications of other conditions. Nevertheless, it goes somewhat beyond the evidence: the link with diabetes as a standalone condition is only found in research in combination with cancer, not for diabetes on its own. Moreover, a large population study shows that a high monocyte-to-lymphocyte ratio (the inverse of LMR) predicts greater mortality risk, which confirms the direction of the claim but through an inverted measure.

Jim Kwik

Author of Limitless Daily and brain coach for athletes, leaders and public figures

Partly
“Outsourcing navigation to GPS devices leads to a decline in the brain's visuospatial intelligence.”
Jim Kwik (Author of Limitless Daily and brain coach for athletes, leaders and public figures) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
Research in humans shows that intensive GPS use is associated with poorer performance on spatial memory and navigation tasks. A study of 50 regular drivers found that more GPS experience is linked to a greater decline in spatial memory over time, and other research involving 249 participants confirms that higher GPS dependency is associated with a weaker sense of spatial orientation. The claim is therefore correct in its direction, but goes beyond the evidence: the studies measure spatial memory and navigation performance, not 'visuospatial intelligence' as a broad brain category. Moreover, one study points out that people also use GPS to supplement their own knowledge, and that the relationship between GPS use and spatial ability is complex.
Partly
“Racket sports make one of the greatest contributions of all sports to longevity and cognitive abilities.”
Jim Kwik (Author of Limitless Daily and brain coach for athletes, leaders and public figures) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with caution
Regarding longevity, two large studies show that racket sports indeed score favourably compared to other sports: in older adults, racket sports ranked at the top for reduction in mortality risk, alongside running, and in elite international athletes, the longevity gains for tennis and badminton players were positive but not the highest (pole vault and gymnastics scored higher in men). For cognitive abilities, the evidence is limited to children and older adults with neurological conditions, and concerns table tennis and tennis individually rather than racket sports as a broad category. The claim that racket sports make "one of the greatest contributions of all sports" holds for longevity in one large study, but for cognition there is no direct comparison with other sports, and one of the studies cited has moreover been retracted. → Do you live longer from playing tennis or squash?

Michael Feldstein

founder and CEO of air purification company Jaspr

Partly
“Working in an office building with clean air leads to cognitive scores 61 to 101 percent higher compared to conventional buildings.”
Michael Feldstein (founder and CEO of air purification company Jaspr) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
One controlled study with 24 office workers does indeed show scores 61% higher in a clean ('green') building and 101% higher in a green building with extra ventilation, compared to a conventional building. Those exact percentages are therefore correct. However, the claim omits an important nuance: the 101% gain applied only to the variant with increased fresh air supply, not to the clean building in itself. Moreover, this is a single small study, and broader research shows that the effects of better ventilation on cognitive performance are far more modest and variable, with improvements of a few percent that are by no means always clearly demonstrable. The claim presents the most favourable outcome as a general conclusion, while the evidence for it rests on a single study.
Partly
“Scent molecules can cross the blood-brain barrier and directly cause changes in blood pressure, brain activity and heart rate.”
Michael Feldstein (founder and CEO of air purification company Jaspr) · Ben Greenfield Life, November 2026 · watch the episode ↗︎ · stated with confidence
Research in humans shows that inhaling scent molecules does indeed produce measurable changes in blood pressure, heart rate and brain activity (EEG), as demonstrated in two studies with human participants who inhaled volatile substances. The idea that scent molecules can travel to the brain via the olfactory nerve is supported by research into what is known as the olfacto-cerebral route. One study also shows that a specific scent molecule (diacetyl) can actually cross the blood-brain barrier, but this concerns animal and laboratory research and does not yet constitute evidence in humans. The claim combines two mechanisms: crossing the blood-brain barrier and direct effects on blood pressure, brain activity and heart rate, yet these two have not been demonstrated simultaneously in humans in the research. Moreover, the physiological effects are also likely explained via the nervous system, not solely by direct passage across the blood-brain barrier.

Josh Dech

Former paramedic, certified nutritionist and gut health specialist

Partly
“Trauma and chronic stress raise cortisol levels and directly cause gut dysregulation and dysbiosis.”
Josh Dech (Former paramedic, certified nutritionist and gut health specialist) · Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
The link between chronic stress and gastrointestinal complaints has been widely studied and is likely causal, but the claim goes beyond the evidence on two points. First, 'elevated cortisol' does not tell the whole story: with prolonged or traumatic stress, the cortisol pattern can actually shift towards lower or irregular levels, not always higher ones. Second, the link with gut dysregulation is strongest for irritable bowel syndrome; for other gastrointestinal conditions the evidence is weaker, and the claim that the mechanism runs directly from cortisol to dysbiosis cannot be substantiated on the basis of available research.

From the episodes, no speaker named

Partly
“Training in hot conditions (heat acclimatisation) can increase VO2 max by about 8% through an increase in cardiac output and plasma volume.”
Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
One study in twelve trained cyclists does indeed show an 8% increase in VO2 max after ten days of heat acclimatisation, combined with an increase in blood plasma and cardiac output. Other studies in humans confirm that heat acclimatisation brings about beneficial adaptations in the heart and blood vessels, but a review of eleven carefully designed studies found no clear effect on VO2 max. Another study in runners likewise found no clear change in VO2 max after heat acclimatisation, while passive heating (hot-water baths) increased VO2 max in a small study through adaptations in blood volume and the heart, not primarily through blood plasma. The figure of 8% therefore comes from one specific study and is not broadly confirmed; the proposed mechanism involving both cardiac output and plasma volume is also only partly, not fully, supported by the evidence.
✓ Holds up
“A nightly sleep duration of between 6.4 and 7.8 hours correlates with the slowest biological organ ageing.”
Ben Greenfield Life, September 2026 · watch the episode ↗︎ · stated with confidence
A large study (published in Nature, 2026) using data from the UK Biobank examined the relationship between sleep and 23 biological ageing clocks for the brain, organs and blood values. It reports precisely the mentioned range of 6.4 to 7.8 hours as the range within which the biological age clocks are at their lowest, with a U-shaped pattern on both sides. This varied by organ and by sex. A second large UK Biobank study also confirms a U-shaped relationship between sleep and biological ageing, with 7 hours per night as the reference point. The claim is therefore well supported by large-scale human research, although these are correlations and self-reported sleep times, not evidence of cause and effect. → Do you age faster if you sleep too little?
Partly
“Greater muscle mass and muscle density in the chest and upper back reduces the risk of a heart attack and death, even in the presence of vascular plaque.”
Ben Greenfield Life, August 2026 · watch the episode ↗︎ · stated with confidence
CT studies do indeed show that greater muscle mass and higher muscle density around the chest and upper back are associated with fewer heart attacks and lower mortality, even in people with vascular plaque. However, this is observational research: it has not been proven that the muscles are the cause. Muscle mass is also an indicator of fitness and overall health in a broader sense.
Newsletter

Stay in the loop

Every Thursday, the most important longevity research in your inbox, focused on what you follow.